Clinical Trials Sponsored by Alnylam Pharmaceuticals
Total 19696 results
-
Alnylam PharmaceuticalsNot yet recruitingMild to Moderate Hypertension
-
Alnylam PharmaceuticalsRecruitingCerebral Amyloid AngiopathyCanada
-
Alnylam PharmaceuticalsRecruitingTransthyretin-Mediated AmyloidosisUnited Kingdom
-
Alnylam PharmaceuticalsActive, not recruitingPrimary Hyperoxaluria Type 1 | Primary HyperoxaluriaUnited States, Italy, France, Lebanon, Belgium, Netherlands, Israel, United Arab Emirates, Australia, Jordan, Turkey
-
Alnylam PharmaceuticalsActive, not recruitingHypertensionUnited States, Canada, Latvia, Poland, United Kingdom, Germany, Lithuania, Estonia, Puerto Rico
-
Alnylam PharmaceuticalsCompletedAmyloid Neuropathies | Amyloid Neuropathies, Familial | TTR-mediated Amyloidosis | Amyloidosis, Hereditary | Amyloidosis, Hereditary, Transthyretin-Related | Familial Amyloid PolyneuropathiesUnited States, Canada, Argentina, Australia, Bulgaria, Cyprus, Italy, Japan, Malaysia, Mexico, Netherlands, Portugal, Spain, Sweden, Germany, France, Brazil, Turkey, Korea, Republic of, Taiwan, United Kingdom
-
Alnylam PharmaceuticalsCompletedTTR-mediated AmyloidosisPortugal, Spain, Sweden, Brazil, United States, France, Germany
-
Alnylam PharmaceuticalsTerminated
-
Alnylam PharmaceuticalsActive, not recruitingTransthyretin Amyloidosis | Amyloidosis, HereditaryUnited States, Argentina, Australia, Belgium, Brazil, Bulgaria, Canada, Cyprus, France, Germany, Greece, Italy, Japan, Korea, Republic of, Malaysia, Mexico, Netherlands, Portugal, Spain, Sweden, Taiwan, United Kingdom
-
Alnylam PharmaceuticalsNo longer availableTransthyretin-mediated Amyloidosis With Cardiomyopathy | ATTR Amyloidosis With CardiomyopathyUnited States
-
Alnylam PharmaceuticalsCompletedPrimary Hyperoxaluria Type 1 (PH1)United States, France, United Kingdom, Switzerland, Netherlands, Israel, Germany, United Arab Emirates
-
Alnylam PharmaceuticalsApproved for marketingPrimary HyperoxaluriaBelgium
-
Alnylam PharmaceuticalsCompletedPolyneuropathy | Hereditary Transthyretin-mediated (ATTRv) AmyloidosisUnited States
-
Alnylam PharmaceuticalsTerminatedAmyloidosis | Leukocyte Chemotactic Factor 2 AmyloidosisUnited States, Malaysia, United Kingdom, Mexico, Egypt, India
-
Alnylam PharmaceuticalsCompletedATTR Amyloidosis | Transthyretin (TTR)-Mediated Amyloidosis | Familial Amyloidotic Polyneuropathy (FAP) | Familial Amyloid NeuropathiesFrance, Germany, Portugal, United Kingdom, Sweden, Spain
-
Alnylam PharmaceuticalsWithdrawnAtypical Hemolytic Uremic SyndromeSweden, Moldova, Republic of, Latvia, Lithuania, Estonia, Bosnia and Herzegovina, Canada, Georgia, Macedonia, The Former Yugoslav Republic of, Serbia
-
Alnylam PharmaceuticalsCompletedTransthyretin-mediated Amyloidosis (ATTR Amyloidosis)United Kingdom
-
Alnylam PharmaceuticalsCompletedRespiratory Syncytial Virus InfectionsUnited States, Australia, Austria, Canada, France, Germany
-
Alnylam PharmaceuticalsCompletedRespiratory Syncytial Virus InfectionsUnited States, Australia
-
Alnylam PharmaceuticalsCompletedFamilial Amyloidotic Cardiomyopathy (FAC)United States, France, Spain, United Kingdom, Belgium, Brazil
-
Alnylam PharmaceuticalsCompleted
-
Alnylam PharmaceuticalsCompletedTTR-mediated AmyloidosisUnited Kingdom
-
Alnylam PharmaceuticalsCompletedSolid TumorsUnited States, Spain
-
Alnylam PharmaceuticalsCompletedElevated LDL-Cholesterol (LDL-C)United Kingdom
-
Alnylam PharmaceuticalsCompletedTransthyretin Mediated Amyloidosis (ATTR)United Kingdom, France, Portugal, Sweden
-
Alnylam PharmaceuticalsRecruitingHereditary Amyloidosis, Transthyretin-Related | Asymptomatic Carrier StateFrance
-
Alnylam PharmaceuticalsRecruitingPolyneuropathy | Hereditary Transthyretin-mediated (hATTR) AmyloidosisNetherlands, Spain, United States, Germany, France, Italy, Portugal
-
Alnylam PharmaceuticalsRecruitingAcute Hepatic PorphyriaBelgium, France, Germany, United Kingdom, United States, Italy, Switzerland, Sweden
-
Alnylam PharmaceuticalsActive, not recruitingTransthyretin Amyloidosis (ATTR) With CardiomyopathyUnited States, Australia, Brazil, Bulgaria, France, Italy, Japan, Mexico, Netherlands, Taiwan, United Kingdom, Belgium, Czechia, Denmark, New Zealand, Sweden, Korea, Republic of, Argentina, Chile, Hong Kong, Portugal
-
Alnylam PharmaceuticalsTerminatedRecurrent Calcium Oxalate Kidney Stone Disease | Elevated Urinary Oxalate LevelsUnited States, Italy, Spain, Belgium, Switzerland, United Kingdom
-
Alnylam PharmaceuticalsApproved for marketingAmyloid Neuropathies | Amyloid Neuropathies, Familial | TTR-mediated Amyloidosis | Amyloidosis, Hereditary | Amyloidosis, Hereditary, Transthyretin-Related | Familial Amyloid Polyneuropathies
-
Alnylam PharmaceuticalsTerminatedNonalcoholic Steatohepatitis | NASHUnited States, Bulgaria, United Kingdom, Belgium, Turkey
-
Alnylam PharmaceuticalsCompletedPrimary Hyperoxaluria | PH1 | RNAi Therapeutic | siRNA | AGTFrance, United Kingdom, Netherlands, Israel, Germany
-
Alnylam PharmaceuticalsCompletedAcute Hepatic Porphyria | Acute Intermittent Porphyria | Porphyria, Acute Intermittent | Acute Porphyria | Hereditary Coproporphyria (HCP) | Variegate Porphyria (VP) | ALA Dehydratase Deficient Porphyria (ADP)United States, Spain, United Kingdom, Korea, Republic of, Australia, Bulgaria, Canada, Denmark, Finland, France, Germany, Italy, Japan, Mexico, Netherlands, Poland, Sweden, Taiwan
-
Alnylam PharmaceuticalsCompletedTTR-mediated AmyloidosisPortugal, Sweden, Brazil, United States, France, Spain, Germany
-
Alnylam PharmaceuticalsCompletedAcute Intermittent PorphyriaUnited States, United Kingdom, Sweden
-
Alnylam PharmaceuticalsActive, not recruitingTransthyretin Amyloidosis (ATTR) With CardiomyopathyUnited States, Poland, Argentina, Australia, Belgium, France, Germany, Japan, Netherlands, Portugal, Spain, Sweden, United Kingdom, Canada, Czechia, Denmark, Hungary, Ireland, Norway, Korea, Republic of, Austria, Croatia, Israel, Latvia, Lithuan... and more
-
Alnylam PharmaceuticalsTerminatedIgA Nephropathy (IgAN) | Berger Disease | Glomerulonephritis, IgACanada, Malaysia, France, Sweden, United Kingdom, Philippines, Singapore, Spain, Taiwan
-
Alnylam PharmaceuticalsCompleted
-
Alnylam PharmaceuticalsCompletedTTR-mediated AmyloidosisUnited States, Canada, United Kingdom
-
Alnylam PharmaceuticalsCompletedParoxysmal Nocturnal Hemoglobinuria (PNH)Spain, United Kingdom
-
Alnylam PharmaceuticalsCompletedPrimary Hyperoxaluria Type 1 (PH1)France, United Kingdom, Netherlands, Israel, Germany
-
Alnylam PharmaceuticalsCompletedPorphyria, Acute Intermittent | Acute Intermittent Porphyria (AIP) | Acute Hepatic Porphyria (AHP) | Acute PorphyriaSweden
-
Alnylam PharmaceuticalsTerminatedHepatitis B | Chronic Hepatitis B | Hepatitis B, Chronic | HBV | Hepatitis B InfectionUnited Kingdom, New Zealand, Singapore, Korea, Republic of, Australia, Hong Kong
-
Alnylam PharmaceuticalsCompletedA Study of the Safety, Tolerability and Pharmacokinetics of ALN-TTR02 in Japanese Healthy VolunteersTransthyretin (TTR)-Mediated AmyloidosisUnited Kingdom
-
Alnylam PharmaceuticalsCompletedRespiratory Syncytial Virus InfectionsUnited States
-
Alnylam PharmaceuticalsRecruitingHypertension | High Cardiovascular RiskUnited States, Canada
-
Alnylam PharmaceuticalsRecruitingType 2 Diabetes Mellitus (T2DM)Canada, United States
-
Alnylam PharmaceuticalsRecruitingEarly-Onset Alzheimer DiseaseUnited Kingdom, United States, Netherlands, Canada
-
Alnylam PharmaceuticalsRecruitingPrimary Hyperoxaluria Type 1France, Spain, United States, Israel, Belgium, Switzerland, Germany, United Kingdom, Italy, Canada